TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant

Contributed by: PR Newswire

Tags

TAHOPharma-Study

More Like This

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

A New Hope for Atrial Fibrillation Patients with Breakthrough Catheter Technology

PR Newswire associated0

Octapharma's continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024

PR Newswire associated0

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Business Wire logo

Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

PR Newswire associated0

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024